| Literature DB >> 25587397 |
Laura Maria Zanoli1, Giuseppe Spoto2.
Abstract
Diagnostic tools for biomolecular detection need to fulfill specific requirements in terms of sensitivity, selectivity and high-throughput in order to widen their applicability and to minimize the cost of the assay. The nucleic acid amplification is a key step in DNA detection assays. It contributes to improving the assay sensitivity by enabling the detection of a limited number of target molecules. The use of microfluidic devices to miniaturize amplification protocols reduces the required sample volume and the analysis times and offers new possibilities for the process automation and integration in one single device. The vast majority of miniaturized systems for nucleic acid analysis exploit the polymerase chain reaction (PCR) amplification method, which requires repeated cycles of three or two temperature-dependent steps during the amplification of the nucleic acid target sequence. In contrast, low temperature isothermal amplification methods have no need for thermal cycling thus requiring simplified microfluidic device features. Here, the use of miniaturized analysis systems using isothermal amplification reactions for the nucleic acid amplification will be discussed.Entities:
Keywords: DNA; isothermal amplification methods; microfluidics; miniaturization
Year: 2012 PMID: 25587397 PMCID: PMC4263587 DOI: 10.3390/bios3010018
Source DB: PubMed Journal: Biosensors (Basel) ISSN: 2079-6374
Figure 1Schematic representation of the loop-mediated isothermal amplification (LAMP) amplification process. Adapted with permission from [40].
Figure 2Schematic representation of helicase-dependent amplification (HDA) amplification process.
Figure 3Principal mechanism for rolling circle amplification (RCA).
Figure 4Schematic representation of nucleic acid sequence-based amplification (NASBA).
Summary of isothermal nucleic acid amplification methods.
| Method | Amplification time | Reaction volume | Target | Detection limit a | Ref. |
|---|---|---|---|---|---|
| LAMP | within 1 h | 25 µL | hepatitis B virus (HBV) DNA | 50 copies/25 μL | [ |
| within 15 min | 10 µL | prostate-specific antigen gene | 23 fg/μL | [ | |
| within 1 h | 5 µL | Pseudorabies virus (PRV) DNA | 10 fg | [ | |
| within 1 h | b | λDNA | two molecule | [ | |
| 1 h | 35 µL | 24 colony forming units (CFU)/mLl | [ | ||
| HDA | 2 h | 150 µL | N. gonorrhoeae genomic DNA | 1 ng | [ |
| 0.5 h | ~5 µL/192 nL | BNI-1 fragment of SARS cDNA | 0.01 ng/μL | [ | |
| 0.5 h | 25 µL | 10 CFU | [ | ||
| RCA | within 65 min | 10 µL | Genomic DNA for | 25 ng | [ |
| 4 h | 2 pL | pIVEX2.2EM-lacZ plasmid | 0.07 pg/μL | [ | |
| 2.5 h | pL | Human-malaria-causing Plasmodium parasites | less than one parasite/μL | [ | |
| MDA | 10–16 h | 60 nL | b | [ | |
| RPA | within 20 min | 10 µL | mecA gene of | less than 10 copies | [ |
| 1 h | 9 nL | Methicillin-resistant | 300 copies/mL | [ | |
| NASBA | within 2 h | 10 nL | Human papillomavirus (HPV) | 1.0 ìM | [ |
| 2,5 h | 80 nL | Artificial human papilloma virus (HPV) 16 sequences | 10−6 ìM | [ | |
| 0,5 h | 2 µL | 100 cells in 100 ìL | [ | ||
| 2–3 h | 30 ìL | Water pathogens | 105 CFU/mL | [ |
a The lowest detected concentration is shown when the detection limit is not reported; b Not available.